The interstitial lung disease (ILD) market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2036, reaching significant expansion due to emerging therapies and improved diagnostics. Key new treatments in development, such as seralutinib, belimumab, and inhaled formulations like treprostinil palmitil inhalation powder, are expected to transform care by targeting multiple disease pathways with better efficacy and safety. The U.S. leads the market with 83% of the 2025 ILD treatment market share, supported by rising disease prevalence and advances in early diagnosis. This growth signals ongoing innovation and investment opportunities in ILD therapeutics.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
